Xinglian Peptide

星联肽生物

Xinglian Peptide

Biotech/Healthcare

Xingliantai Biotech develops protein-drug conjugates and has rapidly built a strong R&D pipeline through a combination of technology licensing and in-house research. The company currently has three products in preclinical development and expects its first product to enter clinical trials in 2024.

Latest round: Angel (2023)

Source: ChinaBulls — chinabulls.com

Last updated 2023-02-01